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HEALTH EQUITY, HPV AND THE CERVICAL
CANCER VACCINE
Joanna N. Erdman*

Technological innovation is primarily valued because it fills an existing health
care gap. This is especially true respecting vaccines in the sexual health context. Behavioural and screening prevention are often seen as temporary
measures until a vaccine is available.1 Vaccines remove the need, and thus
fill the gap, of imperfect prevention.
This article focuses on a different kind of health care gap: health inequity.
It explores the relationship between technological innovation and health
inequity. In particular, the article examines the relationship between the
vaccine against human papillomavirus (HPV) infection, the cause of cervical
cancer, and inequity in cervical cancer incidence and mortality.
In Canada, screening programs have drastically reduced the incidence of
cervical cancer, but their benefits have been unequally distributed. Women
of lower income and literacy, new immigrants, and aboriginal women re2
main significantly more likely both to develop and die of cervical cancer.
The tragedy of cervical cancer is thus not only that it is preventable. It is that
prevention efforts have disproportionately failed the disadvantaged.
Technological innovation alone will not remedy this inequity. The HPV
vaccine merely expands the available means for reducing or enhancing
3
health inequity depending on its implementation. For this reason, the ar-

* Joanna Erdman, Co-Director, International Reproductive and Sexual Health
Law Programme, Faculty of Law, University of Toronto, Toronto, Ontario.
1 Gregory D. Zimet, Rose M. Mays & J. Dennis Fortenberry, “Vaccines Against
Sexually Transmitted Infections: Promise and Problems of the Magic Bullets for
Prevention and Control” (2000) 27 Sexually Transmitted Diseases 49 at 49.
2 Canadian Cancer Society et al., Canadian Cancer Statistics 2007 (Toronto: Canadian
Cancer Society/National Cancer Institute of Canada, 2007) at 17.
3 This analytic framework borrows from Paul H. Wise, “The Anatomy of a Disparity in Infant Mortality” (2003) 24 Annual Review of Public Health 341 at
345: “… medical progress alone can never guarantee equity in health outcomes.
Rather, growing efficacy merely provides an expanded substrate for disparity
reduction or enhancement, depending on patterns of provision.” This frame-
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ticle looks beyond technological innovation to focus on the Canadian HPV
vaccination strategy. It asks: Who is intended to, and who in practice will,
benefit from the vaccine? Will it be women with the least or greatest need?
Will existing health disparities be reduced or enhanced?
The first part of the article discusses the legal significance of health inequity. The second part examines the health equity effects of the Canadian
HPV vaccination strategy.

1. Health Inequity and its Legal Significance
Health inequity is defined as differences in health that “are not only unnecessary and avoidable, but … unfair and unjust.”4 Health inequity thus does
not refer to all differences in health, but focuses on a subset of differences.
It refers to health disparities that are unjust because they are avoidable and
thus unnecessary.
As argued by Paula Braveman, health inequities are identified by their
systematic tracking of existing lines of social disadvantage, including socioeconomic status, race and sex.5 Disadvantaged population groups systematically experience worse health or greater health risks than more advantaged
groups. Systematic association with social disadvantage renders health disparities unjust by positioning health distribution as neither avoidable nor
necessary, but informed by relevant institutions that construct social disadvantage, and thus the health disparities that track it. Health inequity is
located in the social institutions that systematically place already disadvantaged population groups at further disadvantage with respect to their health.
One such institution is the health system. Health inequity is a function of
how health policies and programs are designed and how health resources
are distributed among population groups. In other words, health inequity
6
implicates the ethical and legal principle of distributive justice. The cause

work “is intended to transcend disciplinary antagonisms between the realms of
technical efficacy and social justice.” At 342-43.
4 M. Whitehead, “The concepts and principles of equity in health” (1992) 22 International Journal of Health Services 429 at 429.
5 Paula A. Braveman, “Monitoring Equity in Health and Healthcare: A Conceptual Framework” (2003) 21 Journal of Health Population and Nutrition 181 at
181.
6 Ibid. at 183.
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and more importantly the responsibility for health inequity is located in government action, namely health policies and programs.
The concept of health inequity, and its consequences for government
responsibility, is reflected in the equality rights under s. 15(1) of the Canadian Charter of Rights and Freedoms. Pre-existing disadvantage is identified
as a contextual factor supporting a finding of government discrimination.7
The failure to recognize and address the needs of groups subject to preexisting disadvantage is an especially important indicator of discrimination in
the health context. The Supreme Court has expressly dismissed the claim
that governments are “entitled to provide benefits to the general population
without ensuring that disadvantaged members of society have the resources
to take full advantage of those benefits.”8 A claimed distinction between
state-imposed and pre-existing disadvantage in the design of health policies
and programs “bespeaks a thin and impoverished vision of s. 15(1). It is belied, more importantly, by the thrust of this Court’s equality jurisprudence.”9
Health policy cannot escape constitutional scrutiny because it is facially neutral. On the contrary, the neutrality of a policy, its unresponsiveness to preexisting disadvantage, may render the policy discriminatory. Under s. 15(1),
government must account for health policies and programs that place already disadvantaged social groups at further disadvantage with respect to
their health and healthcare.10
Disparity in HPV-related diseases, in particular cervical cancer, is a
striking instance of health inequity worldwide. A meta-analysis of 57 studies revealed an increased risk of approximately 100% between high and
low social class categories for the development of invasive cervical cancer.11 In Canada, women of lower income and literacy, new immigrants,

7 Law v. Canada (Minister of Employment and Immigration), [1999] 1 S.C.R. 497 at
534, [1999] S.C.J. No. 12.
8 Eldridge v. British Columbia (Attorney General), [1997] 3 S.C.R. 624 at para. 73,
[1997] S.C.J. No. 86 [Eldridge cited to S.C.R.].
9 Ibid.
10 See McKinney v. University of Guelph, [1990] 3 S.C.R. 229, [1990] S.C.J. No. 122,
wherein the Supreme Court of Canada held that the term “law” in Section 15(1)
of the Charter is not confined to formal types of law-making such as statutes and
regulations, but extends to government policies, programs and activities.
11 Seema Parikh, Paul Brennan & Paolo Boffeta, “Meta-Analysis of Social Inequality and the Risk of Cervical Cancer” (2003) 105 International Journal of Cancer
687 at 688.
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and aboriginal women are more likely to both develop and die of cervical
cancer.12
The HPV vaccine is widely regarded as one of the most important technological innovations in women’s health.13 Government accountability extends, however, beyond the opportunity of technological innovation and
policy objectives. It extends to the impact of an HPV vaccination policy on
disadvantaged groups. Will the Canadian vaccination strategy benefit women with the greatest or least need? Will it ensure the best possible health for
the advantaged at the expense of the disadvantaged? Will existing health
disparities be reduced or enhanced? These are the questions of a health equity perspective, the questions of s. 15(1) of the Charter.

2. HPV, Cervical Cancer and the Canadian Vaccination
Strategy
This part of the article examines the Canadian HPV vaccination strategy from
a health equity perspective. Prior to describing the strategy, a brief review of
the science of the human papillomavirus (HPV), cervical cancer and the HPV
vaccine is provided.

A. The Science: HPV and Cervical Cancer
The human papillomavirus (HPV) is a diverse set of more than 100 different virus types. These viruses infect skin and mucous membranes. HPV, for
example, causes benign skin warts. More than 40 HPV types are sexually
transmitted and infect the anogenital (anus and genitalia) region. HPV is
the most prevalent sexually transmitted infection.14 An estimated 75% of all
sexually active women will be infected in their lifetime.15

12 Supra note 2.
13 “To market a drug” The Vancouver Sun (14 May 2007) A11: “When Finance Minister Jim Flaherty announced $300 million in federal money for a program to
vaccinate girls and young women against the human papillomavirus, it was
hailed as the most important development in women’s reproductive health
since the pill.”
14 National Advisory Committee on Immunization (NACI), “An Advisory Committee Statement (ACS): Statement on human papillomavirus vaccine” (2007)
33 Canada Communicable Disease Report 1 at 4: Estimated prevalence and incidence may vary because HPV “is not a nationally notifiable disease in Canada
and, to date, no population-based studies have been published.”
15 Society of Obstetricians and Gynaecologists of Canada, Human Papillomavirus:
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Most infections are asymptomatic and transient. The immune system
resolves the infection in a matter of months.16 Persistent infection over decades with two groups of HPV-types (high risk and low risk) leads to adverse
health outcomes. This classification – high risk and low risk – is based on oncogenic potential or association with invasive cervical cancer.17 Low risk HPV
types are associated with most anogenital warts and mild cervical dysplasia
(precancerous cellular abnormalities). High risk HPV types are associated
with cervical dysplasia, which if left undetected and untreated, may progress
to cervical and other forms of cancer.18
HPV infection and cervical cancer can not therefore be conflated. While
almost all cervical cancers can be traced to high risk HPV infection, the vast
majority of high risk HPV infections clear spontaneously and will not develop into cervical cancer.19

B. Prevention Strategies: Sex, Screening and Vaccination
Three prevention strategies derive from the key role of HPV infection in the
etiology of cervical cancer: sexual behaviour modification, screening and
vaccination.
Sexual activity has been recognized as a factor of cervical cancer risk
since the mid-nineteenth century, based on now controversial statements of
its comparative incidence in prostitutes and nuns.20 Sexual behaviour modification to reduce exposure to HPV, a sexually transmitted infection (STI),

16

17

18

19
20

the most common sexually transmitted infection (Ottawa: Society of Obstetricians and
Gynaecologists of Canada, 2007) at 4.
The Public Health Agency of Canada reports that over 80% of HPV infections
often acquired at an early age clear spontaneously within 18 months. See Public
Health Agency of Canada, Canadian Guidelines on Sexually Transmitted Infections
2006 Edition (Ottawa: Public Health Agency of Canada, 2007).
See Nubia Munoz et al., “Epidemiologic Classification of Human Papillomavirus
Types Associated with Cervical Cancer” (2003) 348 New England Journal of
Medicine, 518.
Cervical cancer is the primary malignancy. Other anogenital cancers (vulva,
vaginal, anus and penile) and cancers of the mouth and upper throat are also
associated with HPV infection.
Supra note 14 at 1, 3.
See e.g. Petr Skradanek, “Cervical Cancer in Nuns and Prostitutes: A Plea for
Scientific Continence” (1988) 41 Journal of Clinical Epidemiology 577.
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is one primary prevention strategy. Safer sex practices include delayed sexual debut, consistent condom use and reduced number of sexual partners.
While the effectiveness of safer sex strategies for HPV infection is debated,21
this prevention strategy carries a significant advantage. It can engage with
upstream determinants of sexual ill-health: social, institutional and other
structural constraints underlying risk behaviours related to sexual health
and well-being. This prevention strategy can thus work to create more supportive sexual health environments.
Screening and vaccination programs, in contrast, focus on the biomedical causes of HPV infection.
The “Pap” (Papanicolaou) smear test is one of the most successful screening tests in the history of medicine. Since its introduction in Canada, this
secondary prevention strategy has dramatically reduced the incidence and
mortality of cervical cancer.22 Screening allows for early detection, followup and treatment of precancerous abnormalities, a viable strategy in cervical
cancer prevention because of the prolonged progression from infection to
23
disease, an estimated ten years or longer.
Despite the success of screening programs, the decline in cervical cancer
incidence in Canada has plateaued. In 2006, an estimated 1,350 new cases
of cervical cancer and 390 cervical cancer-related deaths were reported.24
Cervical cancer rates, more significantly, continue to vary according to indicators of social disadvantage: lower socioeconomic status, lower education
level, birthplaces outside Canada and marginalized ethnicities. Women belonging to socially disadvantaged groups remain at a significantly higher risk
25
of both developing and dying of cervical cancer. Age-standardized rates of
cervical cancer among Canadian Inuit women, for example, are three times

21 The Society of Obstetricians and Gynaecologists of Canada advises that as compared to other STIs – such as chlamydial infection, gonorrhea, syphilis, HIV
infection and hepatitis B – fewer behavioural methods of HPV prevention have
been shown to be effective. HPV infection is also unique in its risk of transmission with very few partners: up to 60% of women are infected by their first
partner. See Marc Steben, “Prevention” (2007) 29:8 Journal of Obstetrics and
Gynaecology Canada S23 at S23.
22 Supra note 14 at 11.
23 Ibid. at 4.
24 Supra note 2 at 20, 22.
25 Ibid. at 17.
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higher than the national average. Elevated cervical cancer rates of 2 to 6
times are reported among aboriginal women in British Columbia, Saskatchewan, Manitoba and Ontario.26
This disparity results not from individual but systemic risk: inaccessible
screening and treatment. 60% of women diagnosed with cervical cancer
in Canada have not been screened or have been inadequately screened.27
Disadvantaged women are disproportionately represented among the unscreened and the untreated.28 This is the consequence of multiple system
barriers, including:
• opportunistic screening that relies on provider initiation,
• lack of primary care or female providers and restrictions on midlevel providers,
• lack of culturally competent care,
• language and literacy differences, and
• failure to address women’s distrust, embarrassment and discomfort in accessing sexual health services.
One answer to the health inequity of screening programs is to reduce
their importance. This can be accomplished by improving the effectiveness
of primary prevention. Rather than focusing on sexual transmission, the
newest primary prevention focuses on the proximal biomedical causes of
HPV infection. The intervention: vaccination.
On July 10, 2006, Health Canada approved the vaccine Gardasil™ (Mer29
ck Frosst Canada Ltd.). Based on the review of data respecting quality,
safety, and effectiveness, Health Canada considered the benefit/risk profile

26 Health Canada, Cervical Cancer Screening in Canada: 1998 Surveillance Report (Ottawa: Public Works and Government Services, 2002).
27 K. Joan Murphy, “Screening for Cervical Cancer” (2007) 29:8 Journal of Obstetrics and Gynaecology Canada S27 at S27.
28 Supra note 14 at 14: “Failure to screen and failure to screen at the recommended
interval are associated with low education and low socio-economic status, rural/remote residence and ethnicity.” See also supra note 26 at ix: “Women who
are older, immigrant or Aboriginal, or who have a lower socio-economic status
are at higher risk of developing cervical cancer, as these groups show lower
compliance with regular screening schedules.”
29 Health Canada, Notice of Decision for Gardasil™, online: Health Canada
<http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/
nd_ad_2006_gardasil_102682-eng.pdf>.
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of the vaccine favourable for the prevention of HPV infection and associated
diseases, including cervical cancer, vulvar and vaginal cancer, genital warts
and precancerous lesions.30 Gardasil protects against initial infection with
two high risk HPV types (16 and 18) which cause approximately 70% of
cervical cancers and two low risk HPV types (6 and 11) which cause approximately 90% of anogenital warts.31 On February 15, 2007, the National Advisory Committee on Immunization (NACI) issued a statement recommending the use of Gardasil™ for Canadian females between nine and twenty-six
years of age.32 The HPV vaccine Cervarix™ (GlaxoSmithKline) is currently
under Health Canada review.
The HPV vaccine carries the potential not simply to reduce but to effectively eradicate cervical cancer. Realization of this potential depends, however, on the extent to which women who have historically failed to benefit
from screening programs can access the vaccine. The success of HPV vaccination depends on its health equity effects. Design and implementation of the
Canadian HPV vaccination strategy is thus paramount to its success.33

C. Implementation Challenges: Sex, Youth and Money
Three characteristics pose challenges to achieving the promised health equity benefits of the HPV vaccine: its characterization as a STI vaccine, its
administration to young adolescents and its exceptionally high cost.
The HPV vaccine is characterized as protecting against diseases caused by
infection with HPV, a sexually transmitted infection (STI).34 As the vaccine
is designed to prevent against initial HPV infection, it is ideally administered

30 Health Canada, Summary Basis of Decision (SBD) Gardasil™ Quadrivalent Human
Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine Merck Frosst Canada Ltd.,
online: Health Canada <http://www.hc-sc.gc.ca/dhp-mps/alt_formats/
hpfb-dgpsa/pdf/prodpharma/sbd_smd_2007_gardasil_102682-eng.pdf>. Health
Canada’s Summary Basis of Decision documents are intended to outline the scientific and regulatory considerations that factor into Health Canada regulatory
decisions related to drugs and medical devices.
31 Supra note 14 at 2-3, 16.
32 Ibid. at 23.
33 See e.g. Debbie Saslow & Cosette M. Wheeler, “Human Papillomavirus Vaccines:
Who Will Pay, Who Will Receive, When to Administer?” (2007) 17 Ethnicity
and Disease S2-8.
34 Merck Frosst Canada Ltd., Product Monograph: Gardasil (Kirkland, QC: Merck
Frosst Canada Ltd., 2006).
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prior to exposure and thus sexual debut. The National Advisory Committee
on Immunization recommends use of Gardasil for females “between 9 and
13 years of age, as this is before the onset of sexual intercourse for most females in Canada, and the efficacy would be greatest.”35
Vaccine acceptance is based in part on perceived susceptibility or risk.36
This factor may pose an implementation challenge for an STI vaccine administered to young adolescents.
In the case of an STI vaccine, risk of infection is associated with sexual and other social behaviours: early age of first sexual intercourse, higher
numbers of or transient sexual partners, inconsistent condom use, having
never married or not living with a sexual partner – traditional markers of
sexual promiscuity. Women, and especially socially disadvantaged women,
may be unwilling to associate themselves with such negatively stereotyped
and stigmatized behaviours. This poses challenges for vaccination programs
intended to target high risk women identified by markers of social disadvantage, such as socioeconomic status or ethnicity. Targeted programs may legitimate stereotypes or perpetuate stigma about the source of higher cervical
cancer rates among these women: sexual and other risk behaviour inherent
to the individual or population group rather than inaccessible screening and
treatment, underlying systemic factors.37
In the case of an STI vaccine administered to young adolescents, parents may be especially unwilling to acknowledge their child’s susceptibility to infection.38 While evidence suggests that most parents will not object
to vaccination on this ground,39 the data is not disaggregated. The sexual
transmission of HPV may be a stronger consideration in families and communities where premarital sex is strictly forbidden. It is, however, young
women from these families and communities who are commonly denied

35 Supra note 14 at 23.
36 Supra note 1 at 51.
37 Anne Schneider & Helen Ingram, “Social construction of target populations: implications for politics and policy” (1993) 87 American Political Science Review
334 at 335.
38 Richard K. Zimmerman, “Ethical analysis of HPV vaccine policy options” (2006)
24 Vaccine 4812 at 4814.
39 Gregory D. Zimet, “Understanding and overcoming barriers to human papillomavirus vaccine acceptance” 18 Current Opinion in Obstetrics and Gynecology
S23 at S24-25.
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sexual health information, education and services, and who would therefore
benefit most from vaccination.
Cost is also a significant factor in vaccine acceptance.40 With a purchase
cost of $404.85,41 Gardasil is the most expensive vaccine ever developed for
mass use.42 Poor and low income women are a large proportion of women systemically denied the benefits of screening. If women are required to
privately pay for the vaccine, women with the greatest need will again be
denied access to preventative care.43 The HPV vaccine will contribute little
to decreasing cervical cancer incidence and mortality if it is inaccessible to
disadvantaged population groups with the greatest risk of developing and
dying of cervical cancer.

D. The Canadian Strategy: School-Based Publicly-Funded
Cancer Vaccination
The health equity challenges of the HPV vaccine are not insurmountable.
On the contrary, the Canadian strategy is expressly designed to address these
concerns. The strategy: school-based, publicly funded Cancer vaccination.
On March 19, 2007, the Federal Government announced that it would
contribute $258 million on a per capita basis to implement provincial and
territorial HPV vaccination programs over the next three years.44 In 2007,
Nova Scotia, Newfoundland and Labrador, Prince Edward Island, and Ontario
offered Gardasil on a voluntary basis with parental consent as part of school-

40 Supra note 1 at 51; supra note 38.
41 Andre Lalonde, “Cost-Benefit Analysis of HPV Vaccination” (2007) 29:8 Journal
of Obstetrics and Gynaecology Canada S43 at S48. See also Patented Medicines
Prices Review Board, “Report on New Patented Drugs – Gardasil,” online: Patented Medicines Prices Review Board <http://www.pmrb-cepmb.gc.ca/english/
view.asp?x=924&mp=572&pf=1>. The introductory price of Gardasil is listed at
approximately $135 per dose with three doses required.
42 Abby Lippman et al.,. “Human papillomavirus, vaccines and women’s health:
questions and cautions” (2007) 177 Canadian Medical Association Journal 484
at 485.
43 Ibid. at 486: “if and when evidence shows that an HPV vaccination program
can be successfully implemented in Canada, it must be publicly funded. Lack of
financial resources must not preclude any girl or woman from receiving what
has been sanctioned by health officials.”
44 James M. Flaherty, The Budget Speech 2007: Aspire to a Stronger, Safer, Better Canada
(Ottawa: Department of Finance Canada, 2007) at 10.
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based vaccination programs. The programs target girls in Grades 6, 7 or 8. British Columbia and Quebec are expected to begin school programs in 2008.
The Canadian strategy offers a number of advantages from a health equity perspective.
The strategy (with Merck’s lead) re-characterizes and promotes the vaccine as a “cancer vaccine.”45 This re-characterization addresses two factors of
vaccine acceptance: disease severity and perceived susceptibility.46
Cancer relative to STIs is perceived as a more serious disease. In the
Product Monograph for Gardasil, cervical cancer is described as a “serious
and sometimes life threatening disease.”47 Provincial governments likewise
emphasize the severity of cervical cancer in support of their vaccination
programs. The Government of Newfoundland and Labrador, for example,
describes the vaccine as “one of the first and most successful steps young
women can take to prevent cervical cancer and we want them to have the
best advantage to avoid this terrible disease.”48 The website of the Ontario
Ministry of Health and Long Term Care reads, “Cervical cancer is a serious
disease that affects far too many women in Ontario. The HPV vaccination
will help protect your daughter from this terrible disease.”49
The focus on cervical cancer also affects perceived susceptibility. The
Gardasil™ Product Monograph describes cervical cancer as “start[ing] when
a female catches certain types of HPV … [y]ou or your child cannot get cancer of the cervix without first having an HPV infection.”50 It then proceeds
to describe how “HPV is a common virus … In the absence of vaccination, it
is estimated that 75% of sexually active Canadians will catch Human Papillomavirus during their lifetime.”51 The Product Monograph explains that
“[w]hile most people clear the virus, those who don’t can develop cervical
cancer.”52

45
46
47
48
49

50
51
52

See e.g. supra note 39 at S24.
Supra note 1 at 51.
Supra note 34.
Health and Community Services, News Release, “Newfoundland and Labrador
to Roll Out HPV Vaccination Program in September” (6 August 2007).
Ministry of Health and Long-Term Care, “About the HPV Vaccine,” online: Ontario’s Grade 8 HPV Vaccination Program, online:
<http://www.hpvontario.ca/aboutonvaccine.html>.
Supra note 34.
Ibid.
Ibid.
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By emphasizing the high risk of HPV infection and the necessary link
between HPV and cervical cancer, the Product Monograph intuitively builds
a conflated perception of high risk for cervical cancer. It is interesting to note
that the monograph describes those at risk for HPV, namely 75% of all sexually active Canadians, but not those at risk for cervical cancer. Like many
cancers and unlike STIs, the development of cervical cancer is disassociated
from personal fault or deviant sexual behaviour.
The strategy of framing Gardasil as a vaccine against a severe disease
to which all women are susceptible provides the basis for universal schoolbased programs which by definition include the disadvantaged. On the website of the Ontario Ministry of Health and Long Term Care, it is explained
that “[t]he HPV vaccination program is being implemented within First Nations communities in a manner consistent with the other publicly funded
school-based vaccination programs … All females in Grade 8 will be offered
the HPV vaccine.”53 School-based programs further remove the need for parents to expressly acknowledge the reasons for or to actively seek vaccination
of their daughters, thereby diminishing access disparities on this basis.
The public funding of school-based programs also counters cost concerns.
As reported in the Ottawa Citizen, with the announcement of its $258 million
contribution, the federal government stated: “This is an expensive vaccine
and ... the whole purpose is to make it available to people across Canada,
women and girls across Canada, regardless of their ability to pay.”54
For these reasons, the Canadian vaccination strategy can be characterized as equity promoting.

E. Health Inequity: Of Continued Concern
As always, however, the solution itself proves problematic. In resolving one
set of equity challenges, the Canadian strategy creates a new set. This section
considers how school-based publicly-funded cancer vaccination programs
may reduce rather than enhance health inequity, and how they may do so
with more serious and lasting consequences.
Governments have not positioned vaccination programs as serving
health equity or distributional goals. Rather than challenging ideological

53 Ministry of Health and Long-Term Care, “FAQ,” online: Ontario’s Grade 8 HPV
Vaccination Program <http://www.hpvontario.ca/faq1.html>.
54 K. DeRosa, “Government announces cash for HPV vaccine” The Ottawa Citizen
(17 April 2007) C5.
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frameworks and existing definitions of public health priorities, governments
have worked within existing efficiency rather than equity frameworks to
gain public support. This may prove problematic on both ethical and efficiency grounds.
Women’s health advocates have criticized the strategy of conflating HPV
infection and cervical cancer – of creating the false perception of a cervical
cancer epidemic – to secure public support for universal programs.55 While
a majority of women will be infected with HPV, the vast majority of infections will not develop into cervical cancer. Many of the young women
who will receive the vaccination are at a low lifetime risk of developing
cancer. This heterogeneity of risk renders the HPV vaccine different from
other public health vaccines. In the Canadian context, modelling predicts
that to avoid one case of cervical cancer will require the vaccination of 324
girls; to avoid one death from cervical cancer will require the vaccination
of 729 girls – with life-long duration of vaccine protection.56 These facts are
reported to have affected parental perceptions of susceptibility. Parents may
be unwilling to risk vaccination of uncertain immunity duration to prevent
a disease unlikely to develop for decades and which may largely be protected
against with screening, early detection and treatment. Less than half of Ontario parents consented to their daughters’ vaccination in the first year of the
province’s program.57
The following ethical questions are thus presented: Is it ethical to build a
school-based vaccination program on the false perception of a public health
crisis? Is it ethical if necessary and intended to ensure access for disadvantaged population groups?
The focus on cervical cancer also proves ethically problematic from a
gender equity perspective. Locating the responsibility for sexual heath in
young women reinforces gender stereotypes. While cervical cancer is a sexspecific disease, the prevalence rate of HPV infection, the necessary cause of

55 Supra note 42 at 484: “There is no epidemic of cervical cancer in Canada to
warrant the sense of urgency for a vaccination program initiated by the federal
finance minister’s announcement.” See also Roberta Avery, “Risk of cervical
cancer distorted, causes alarm” The Toronto Star (27 September 2007).
56 Marc Brisson et al., “Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection” (2007) 177 Canadian Medical Association Journal 464 at 466.
57 Judy Gerstel, “Perspectives on the HPV Vaccine” The Toronto Star (10 January
2008).
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cervical cancer, is similar in men and women. There is a high rate of transmission of HPV in female partners of men with pre-existing penile warts,
and HPV infection in men has been shown to contribute to HPV infection
and subsequent cervical disease in women.58 Vaccinating males could thus
provide indirect health benefits for women, but also offer important protection against other cancers, precancerous lesions and genital warts, which
affect both women and men. While the characterization of the HPV vaccine
as a cancer rather than STI vaccine may serve important health equity goals,
it risks reinforcing a gender stereotype that women should take sole responsibility for sexual health.59 Australia, Mexico, and the European Union have
all approved the use of the vaccine for use in males.
The Canadian vaccination strategy also raises concerns of inefficiency.
The heterogeneity of risk for cervical cancer, and thus the vaccination of
women at minimal risk and with negligible need, suggests that targeted implementation may be more efficient. Such is the dilemma of targeted programs: the risk of stigmatization versus the commitment of public funds to
those with the greatest need.60 In universal programs, public funding for
cervical cancer prevention will be wasted on populations well protected by
screening programs.61 Attributable additional lives saved will be few. Moreover, given that no provincial program is truly universal, these resources
could be redeployed to disadvantaged populations with the real capacity to
benefit. The program is thus not only wasteful, but inequitable: the vaccine
benefits accrue to the advantaged at the expense of the disadvantaged.
Interestingly, these ethical and efficiency concerns are often countered
by returning to an STI characterization of the vaccine. Women with minimal
risk of developing cervical cancer nevertheless receive significant benefits

58 Anna R. Giuliano, “Human papillomavirus vaccination in males” (2007) 107
Gynecologic Oncology S24 at S26.
59 Inmaculada De Melo-Martín, “The Promise of the Human Papillomavirus Vaccine Does Not Confer Immunity Against Ethical Reflection” (2006) 11 The Oncologist 393 at 395.
60 Bernard Lo, “Human papillomavirus vaccination programmes” (2007) 335 BMJ
357 at 357.
61 Supra note 42 at 486: “We must be certain that spending an estimated $2 billion
to vaccinate a population of girls and women in Canada who are already mostly
well protected by their own immune systems, safer sex practices and existing
screening programs will not perpetuate the existing gaps in care and leave the
actual rate of deaths from cervical cancer unchanged.”
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from the vaccine: they avoid the stigma of a STI, the pain and discomfort
of genital warts, and the distress and invasive procedures associated with
abnormal screening results and treatment. This re-characterization carries,
however, significant risk. The shift from a cancer to a STI vaccine risks jeopardizing the very rationale for – and the associated health equity benefits of
– a universal vaccination program.
A further counter-argument addressing efficiency concerns requires
that an analysis account for public spending and savings of system-wide
changes. Simply adding vaccination to existing screening programs may not
be an efficient use of resources, but this is not the strategy. Research suggests that unless screening programs are modified, the immunization costs
will strongly outweigh the health care resources, including treatment costs,
saved through vaccination.62
The National Advisory Committee on Immunization advises, for example, that “[a]s more females receive the vaccine the screening programs may
be modified in either type and/or frequency of screening. This is an area
requiring careful research and surveillance before guidelines can change.”63
Careful research and surveillance is required because screening program
modifications carry the greatest risk of adverse health equity effects.64 Diversion from screening to vaccination may not only fail to reduce, but may
enhance health inequity.
The vaccine is not a substitute for routine screening. It protects against
infection with two high risk HPV types responsible for 70% of cervical cancer. The National Advisory Committee on Immunization thus advises that
“women should still expect to take part in the currently recommended

62 Marc Brisson et al., “The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada” (2007) 25 Vaccine 5399 at 5406. See also Sue
Goldie, “A public health approach to cervical cancer control: Considerations of
screening and vaccination strategies” (2006) 94 International Journal of Gynecology and Obstetrics S95.
63 Supra note 14 at 24.
64 It is worthwhile to note that the Ontario Ministry of Health and Long-Term
Care addresses screening program concerns on its HPV information website.
“Maintaining and strengthening Ontario’s cervical cancer screening program
continues to be a priority. Introducing the HPV vaccination program is in no
way an indication of any intention to relax cervical cancer screening in Ontario.” Supra note 53.
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cervical cancer screening programs.”65 A shift in focus from screening to
vaccination may leave disadvantaged women with greater risk of developing cervical cancer from remaining high risk HPV types. Screening also remains critically important for women already exposed to HPV or who do
not receive the vaccine. Women who immigrate to Canada, for example,
cannot benefit from school-based vaccination. Those who cannot privately
afford the vaccine remain dependent on screening programs. The danger to
be avoided is the neglect of successful screening programs for the promised
but unrealized potential of universal vaccination. With a focus on primary
prevention, governments may be even less inclined – the political will for
cervical cancer exhausted – to implement repeated recommendations of expert groups for nationwide comprehensive organized screening to reach disadvantaged women.66
More problematically, the shift from screening to vaccination represents
a shift from the health system to disease-control interventions. A schoolbased vaccination program can be implemented as a vertical program without any spillover effects on health system structures that remain profoundly inequitable. This is unlike investment in screening, an often integrated
component of comprehensive reproductive and sexual health care.67 System
level change could improve young women’s access to comprehensive sexual
health education, information and services.68 Linking the HPV vaccine with
other sexual health interventions, including family planning and other STI
prevention, may be an important opportunity to improve broader sexual
health and well-being.
A focus on vaccine programs, without consideration of the systemic inequality in the health system, diverts attention away from government responsibility for existing health disparity. Women who die of cervical cancer
in Canada are disadvantaged women ill-served by the current health system.
A policy focused on a disease-specific technological innovation neglects the
complex and enduring problem of system-wide health inequity.

65 Supra note 14 at 24.
66 Supra note 27.
67 Canadian Women’s Health Network, HPV, Vaccines, and Gender: Policy Considerations (Winnipeg: Canadian Women’s Health Network, 2007).
68 A.E. Pollack et al.,“Ensuring access to HPV vaccines through integrated services:
a reproductive health perspective” (2007) 85 Bulletin of the World Health Organization 57 at 59.
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Conclusion
Examination of the relationship between technological innovation and
health inequity returns in conclusion to government responsibility. It is undisputed that the HPV vaccine is a most welcome innovation in women’s
health. Precisely for this reason, the Canadian strategy must ensure the vaccine’s availability among disadvantaged population groups with the greatest
need and thus capacity to benefit. The value of health equity must play an
important role in government accountability. This is true both in setting the
direction of health policy and in ongoing surveillance to ensure that health
inequities are reduced rather than enhanced over time.
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